Drug Profile
Tobramycin inhalation - PARI Pharma
Alternative Names: PARI Tobramycin 100; T 100 - PARI; Tobramycin Pari; VantobraLatest Information Update: 29 Nov 2022
Price :
$50
*
At a glance
- Originator PARI Pharma GmbH
- Developer Centre for Human Drug Research; PARI Pharma GmbH
- Class Aminoglycosides; Anti-infectives; Antibacterials; Antibronchitics; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Cystic fibrosis-associated respiratory tract infections
- No development reported Asthma
Most Recent Events
- 29 Nov 2022 No development reported - Phase-II for Asthma in Netherlands (Inhalation)
- 20 Dec 2017 Phase-II clinical trials in Asthma in Netherlands (Inhalation) (EudraCT2017-003177-34)
- 18 Mar 2015 Registered for Cystic fibrosis-associated respiratory tract infections in European Union, Liechtenstein, Iceland and Norway (Inhalation)